WallStreetZenWallStreetZen

NASDAQ: GENB
Generate Biomedicines Inc Earnings Dates, Reports, Calls

OverviewEarnings
RevenueDividendOwnership
Generate Biomedicines earnings were -$249.5M for the trailing 12 months ending Dec 31, 2025, with N/A growth year over year. The latest GENB earnings report on Dec 31, 2025 announced Q4 2025 earnings of N/A, down N/A from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, GENB reported annual earnings of -$249.5M, with 16.7% growth.

GENB earnings history

Current Revenue
$31.9M
Current Earnings
-$249.5M
Current Profit Margin
-782.4%

GENB Return on Equity

Insufficient data to display

GENB Return on Assets

Current Company
-58.8%
Current Industry
-4.8%

Be the first to know when GENB announces earnings.

GENB Return on Capital Employed

Current Company
-81.4%
Current Industry
1.5%

GENB vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
AARD-$48.34M-$48.77MN/A-$4.30
ACET-$105.29M-$115.01MN/A-$20.00
ABUS-$41.48M-$42.28MN/A-$0.23
ABVC-$6.96M-$7.91MN/A-$0.39
AAPGN/A-$161.45MN/A-$2.02
View Top Biotech Stocks

Generate Biomedicines Earnings Reports & History FAQ

What were Generate Biomedicines's earnings last quarter?

Generate Biomedicines (NASDAQ: GENB) reported Q4 2025 earnings per share (EPS) of N/A, up N/A year over year. Total GENB earnings for the quarter were N/A. In the same quarter last year, Generate Biomedicines's earnings per share (EPS) was N/A.

If you're new to stock investing, here's how to buy Generate Biomedicines stock.

Is Generate Biomedicines profitable or losing money?

As of the last Generate Biomedicines earnings report, Generate Biomedicines is currently losing money. Generate Biomedicines's net profit (also called net income) for the twelve months ending Dec 31, 2025 was -$203.15 million, a 16.91% increase year over year.

What was GENB's earnings growth in the past year?

As of Generate Biomedicines's earnings date in Q1 2026, Generate Biomedicines's earnings has grown year over year. GENB earnings in the past year totalled -$249.52 million.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.